Robert Sabat

Dr. Robert Sabat

Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
RSRobert Sabat
Robert Sabat
GGGerald Grütz
Gerald Grütz
KWKatarzyna Warszawska
Katarzyna Warszawska
SKStefan Kirsch
Stefan Kirsch
EWEllen Witte
Ellen Witte
JGJens Geginat
Jens Geginat

25 April 2006 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
KWKerstin Wolk
Kerstin Wolk
EWEllen Witte
Ellen Witte
EWElizabeth Wallace
Elizabeth Wallace
WDWolf‐Dietrich Döcke
Wolf‐Dietrich Döcke
SKStefanie Kunz
Stefanie Kunz
RSRobert Sabat
Robert Sabat
IL‐22 is an IFN–IL‐10 cytokine family member, which is produced by activated Th1 and NK cells and acts primarily on epithelial cells. Here we demonstrate that IL‐22, in contrast to its relative IFN‐γ, regulates the expression of only a few genes in keratinocytes. This is due to varied signal transduction. Gene expressions regulated by IL‐22 should enhance antimicrobial defense [psoriasin (S100A7), calgranulin A (S100A8), calgranulin B (S100A9)], inhibit cellular differentiation (e.g., profilaggrin, keratins 1 and 10, kallikrein 7), and increase cellular mobility [e.g., matrix metalloproteinease 1 (MMP1, collagenase 1), MMP3 (stromelysin 1), desmocollin 1]. In contrast, IFN‐γ favored the expression of MHC pathway molecules, adhesion molecules, cytokines, chemokines, and their receptors. The IL‐22 effects were transcriptional and either independent of protein synthesis and secretion, or mediated by a secreted protein. Inflammatory conditions, but not keratinocyte differentiation, amplified the IL‐22 effects. IL‐22 application in mice enhanced cutaneous S100A9 and MMP1 expression. High IL‐22 levels in psoriatic skin were associated with strongly up‐regulated cutaneous S100A7, S100A8, S100A9, and MMP1 expression. Psoriatic patients showed strongly elevated IL‐22 plasma levels, which correlated with the disease severity. Expression of IL‐22 and IL‐22‐regulated genes was reduced by anti‐psoriatic therapy. In summary, despite similarities, IFN‐γ primarily amplifies inflammation, while IL‐22 may be important in the innate immunity and reorganization of epithelia.

12 March 2020 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
RSRobert Sabat
Robert Sabat
GJGregor B. E. Jemec
Gregor B. E. Jemec
ŁMŁukasz Matusiak
Łukasz Matusiak
AKAlexa B. Kimball
Alexa B. Kimball
EPErrol Prens
Errol Prens
KWKerstin Wolk
Kerstin Wolk

21 June 2017 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
Christos C. ZouboulisChristos C. Zouboulis
Christos C. Zouboulis
TTT Tzellos
T Tzellos
AKATHANASSIOS KYRGIDIS
ATHANASSIOS KYRGIDIS
GJG B E Jemec
G B E Jemec
FBF G Bechara
F G Bechara
EGEuropean Hidradenitis Suppurativa Foundation Investigator Group
European Hidradenitis Suppurativa Foundation Investigator Group
Background A validated tool for the dynamic severity assessment of hidradenitis suppurativa/acne inversa (HS) is lacking. Objectives To develop and validate a novel dynamic scoring system to assess the severity of HS. Methods A Delphi voting procedure was conducted among the members of the European Hidradenitis Suppurativa Foundation (EHSF) to achieve consensus towards an initial HS Severity Score System (HS4). Strengths and weaknesses of HS4 were examined by a multicentre prospective study. Multivariate logistic regression, discriminant analysis and receiver operating characteristic curves, as well as examination for correlation (Spearman's rho) and agreement (Cohen's kappa) with existing scores, were engaged to recognize the variables for a new International HS4 (IHS4) that was established by a second Delphi round. Results Consensus HS4 was based on number of skin lesions, number of skin areas involved and Dermatology Life Quality Index (DLQI), and was evaluated by a sample of 236 patients from 11 centres. Subsequently, a multivariate regression model calculated adjusted odds ratios for several clinical signs. Nodules, abscesses and draining tunnels resulted as the scoring variables. Three candidate scores were presented to the second Delphi round. The resulting IHS4 score is arrived at by the number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A total score of 3 or less signifies mild, 4–10 signifies moderate and 11 or higher signifies severe disease. Cohen's kappa was fair (κ = 0·32) compared with Hurley classification, and moderate (κ = 0·49) compared with Expert Opinion. Correlation was good (ρ > 0·6) with Hurley classification, Expert Opinion, Physician's Global Assessment and Modified Sartorius score, and moderate for DLQI (ρ = 0·36). Conclusions The novel IHS4 is a validated tool to dynamically assess HS severity and can be used both in real‐life and the clinical trials setting.

30 March 2009 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
KWKerstin Wolk
Kerstin Wolk
HHHarald S. Haugen
Harald S. Haugen
WXWenfeng Xu
Wenfeng Xu
EWEllen Witte
Ellen Witte
KWKim Waggie
Kim Waggie
RSRobert Sabat
Robert Sabat

5 September 2007 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
RSRobert Sabat
Robert Sabat
SPSandra Philipp
Sandra Philipp
CHConny Höflich
Conny Höflich
SKStefanie Kreutzer
Stefanie Kreutzer
EWElizabeth Wallace
Elizabeth Wallace
KWKerstin Wolk
Kerstin Wolk
Abstract:  Psoriasis is a chronic skin disease that affects about 1.5% of the Caucasian population and is characterized by typical macroscopic and microscopic skin alterations. Psoriatic lesions are sharply demarcated, red and slightly raised lesions with silver‐whitish scales. The microscopic alterations of psoriatic plaques include an infiltration of immune cells in the dermis and epidermis, a dilatation and an increase in the number of blood vessels in the upper dermis, and a massively thickened epidermis with atypical keratinocyte differentiation. It is considered a fact that the immune system plays an important role in the pathogenesis of psoriasis. Since the early 1990s, it has been assumed that T1 cells play the dominant role in the initiation and maintenance of psoriasis. However, the profound success of anti‐tumor necrosis factor‐α therapy, when compared with T‐cell depletion therapies, should provoke us to critically re‐evaluate the current hypothesis for psoriasis pathogenesis. Recently made discoveries regarding other T‐cell populations such as Th17 and regulatory T cells, dendritic cells, macrophages, the keratinocyte signal transduction and novel cytokines including interleukin (IL)‐22, IL‐23 and IL‐20, let us postulate that the pathogenesis of psoriasis consists of distinct subsequent stages, in each of them different cell types playing a dominant role. Our model helps to explain the varied effectiveness of the currently tested immune modulating therapies and may enable the prediction of the success of future therapies.